New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
November 5, 2019 - Sandoz announced the FDA approval of Ziextenzo (pegfilgrastim-bmez), a biosimilar to Amgen’s Neulasta® (pegfilgrastim)
Download PDF
Return to publications
